0
Signin
countryflagCA

888-969-2592

RY 144.17 0.4529% TD 77.39 0.0517% SHOP 78.87 -1.3878% CNR 171.64 0.5625% ENB 50.09 -0.4769% CP 110.62 0.6277% BMO 128.85 -0.548% TRI 233.58 1.1563% CNQ 103.29 -0.174% BN 60.87 -0.2295% ATD 75.6 -1.447% CSU 3697.0 1.1582% BNS 65.76 -0.3485% CM 66.6 -0.5525% SU 54.21 1.1569% TRP 53.15 0.3398% NGT 58.54 -0.3405% WCN 226.5 0.4123% MFC 35.905 0.9986% BCE 46.75 -0.5954%

Intelgenx Technologs

Healthcare CA IGX

0.24CAD
0.04(17.07%)

Last update at 2024-05-16T13:30:00Z

Day Range

0.210.24
LowHigh

52 Week Range

0.140.35
LowHigh

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -10.69000M -9.31800M -7.04400M -10.66000M -10.10800M
Minority interest - - - - -
Net income -10.69000M -9.31200M -7.04400M -10.66000M -10.10800M
Selling general administrative 4.70M 3.75M 4.44M 5.80M 5.00M
Selling and marketing expenses - - - - -
Gross profit -0.90800M -0.72100M 1.54M 0.74M 1.82M
Reconciled depreciation 0.78M 0.79M 0.73M 0.72M 0.72M
Ebit -9.40900M -7.83000M -5.84200M -9.45300M -8.98700M
Ebitda -8.63200M -7.03900M -5.10800M -8.73500M -8.26800M
Depreciation and amortization 0.78M 0.79M 0.73M 0.72M 0.72M
Non operating income net other - - - - -
Operating income -9.41300M -7.98200M -6.26400M -9.55000M -8.99800M
Other operating expenses 10.36M 9.52M 7.81M 10.29M 10.82M
Interest expense 1.28M 1.49M 1.20M 1.21M 1.12M
Tax provision 0.00000M -0.00600M 0.00000M 0.00000M 0.00000M
Interest income 1.28M 0.15M 0.78M 1.11M 1.11M
Net interest income -1.27700M -1.33600M -0.78000M -1.11000M -1.11000M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.00400M -0.00600M 0.42M 0.10M 0.01M
Total revenue 0.95M 1.53M 1.54M 0.74M 1.82M
Total operating expenses 8.51M 7.26M 7.81M 10.29M 10.82M
Cost of revenue 1.86M 2.26M - - 0.00000M
Total other income expense net -1.27700M -1.33600M -0.78000M -1.11000M -1.11000M
Discontinued operations - - - - -
Net income from continuing ops -10.69000M -9.31200M -7.04400M -10.66000M -10.10800M
Net income applicable to common shares -10.69000M -9.31200M -7.04400M -10.66000M -10.10800M
Preferred stock and other adjustments - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 9.19M 17.91M 11.12M 11.02M 20.02M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 0.33M 0.31M 0.57M 0.17M 0.46M
Total liab 12.61M 14.03M 12.07M 10.73M 10.03M
Total stockholder equity -3.42300M 3.87M -0.95300M 0.29M 9.99M
Deferred long term liab - - - - -
Other current liab 2.10M 2.30M 1.99M 1.94M -
Common stock 0.00100M 0.00100M 0.00100M 0.00100M 0.00100M
Capital stock 0.00100M 0.00100M 0.00100M 0.00100M 0.00100M
Retained earnings -68.53000M -57.86300M -48.55100M -41.50700M -30.89600M
Other liab - 0.08M - - 0.05M
Good will - - - - -
Other assets 0.24M 0.25M 0.25M 0.75M 0.71M
Cash 1.21M 3.94M 1.21M 1.33M 6.82M
Cash and equivalents - 3.94M 1.21M 1.33M 6.82M
Total current liabilities 2.37M 7.02M 4.37M 8.45M 2.72M
Current deferred revenue - 0.19M 0.17M - -
Net debt 9.30M 7.52M 8.71M 7.45M 1.14M
Short term debt 0.27M 4.53M 2.21M 6.51M 0.69M
Short long term debt - 4.25M 2.05M 6.37M 0.69M
Short long term debt total 10.51M 11.47M 9.92M 8.79M 7.95M
Other stockholder equity 67.34M 63.10M 48.45M 42.63M 42.05M
Property plant equipment 5.16M 6.22M 6.56M 7.05M 6.25M
Total current assets 3.79M 11.44M 4.30M 3.22M 13.06M
Long term investments - - - - -
Net tangible assets -3.42300M 3.87M -0.95300M 0.29M 9.99M
Short term investments 1.32M 6.00M 1.04M 0.58M 4.18M
Net receivables 0.87M 1.12M 1.25M 0.76M 1.23M
Long term debt 9.77M 6.21M 7.14M 1.73M 7.26M
Inventory 0.06M 0.06M 0.24M 0.38M 0.38M
Accounts payable 2.10M 2.30M 1.99M 1.94M 2.03M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -2.23400M -1.37100M -0.85600M -0.83600M -1.16600M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.24M 0.25M 0.25M 0.75M 0.71M
Deferred long term asset charges - - - - -
Non current assets total 5.40M 6.47M 6.81M 7.80M 6.96M
Capital lease obligations 0.74M 1.01M 0.73M 0.69M -
Long term debt total 9.81M 6.29M 7.22M 1.73M 7.26M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 3.51M -4.96600M -0.40600M 3.73M -1.08100M
Change to liabilities -0.26100M 0.31M 0.10M -0.16300M 0.56M
Total cashflows from investing activities 3.51M -5.07400M -0.52600M 3.21M -2.17700M
Net borrowings - 3.63M 1.13M -0.71100M -0.74900M
Total cash from financing activities 2.96M 15.49M 6.24M -0.69000M 16.40M
Change to operating activities -0.04100M 0.26M 0.12M 0.29M -0.27100M
Net income -10.69000M -9.31200M -7.04400M -10.66000M -10.10800M
Change in cash -2.73500M 2.74M -0.12700M -5.48300M 5.22M
Begin period cash flow 3.94M 1.21M 1.33M 6.82M 1.59M
End period cash flow 1.21M 3.94M 1.21M 1.33M 6.82M
Total cash from operating activities -9.51600M -7.17300M -5.76800M -8.19900M -8.53000M
Issuance of capital stock 0.00000M 12.35M 5.56M 0.00000M 15.41M
Depreciation 0.78M 0.79M 0.73M 0.72M 0.72M
Other cashflows from investing activities 3.78M -4.96600M -0.40600M 3.73M -1.08100M
Dividends paid - - - - -
Change to inventory 0.00000M 0.18M 0.14M 0.14M -0.37500M
Change to account receivables -0.02900M -0.42000M 0.12M 0.43M -0.19200M
Sale purchase of stock 0.00000M 12.35M 5.56M 0.02M 17.74M
Other cashflows from financing activities 3.00M 3.91M 1.15M 0.02M 1.74M
Change to netincome 0.45M 0.66M 0.42M 1.19M 1.14M
Capital expenditures 0.27M 0.11M 0.12M 0.53M 1.10M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -0.05400M 0.69M 0.12M 0.56M -0.28200M
Stock based compensation 0.11M 0.11M 0.19M 0.33M 0.37M
Other non cash items 0.34M 0.56M 0.23M 0.85M 0.77M
Free cash flow -9.78700M -7.28100M -5.88800M -8.72400M -9.62600M

Fundamentals

  • Previous Close 0.20
  • Market Cap37.69M
  • Volume7000
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-9.27100M
  • Revenue TTM0.79M
  • Revenue Per Share TTM0.005
  • Gross Profit TTM -0.90800M
  • Diluted EPS TTM-0.08

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (CAD) Price (CAD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
IGX
Intelgenx Technologs		 0.04 17.07% 0.24 - - 47.95 11.85 71.05 -6.0429
FRX
Fennec Pharmaceuticals Inc		 -0.19 2.00% 9.33 - 33.33 29.10 84.57 30.47 -23.3985
SVA
Sernova Corp		 -0.025 7.14% 0.33 - - - 7.95 -4.4095
EPRX
Eupraxia Pharmaceuticals Inc		 -0.01 0.25% 4.00 - - - 8.40 -3.9163
TH
Theratechnologies Inc.		 0.01 0.56% 1.81 - 55.25 1.64 19.46 2.23 -11.7353

Reports Covered

Stock Research & News

View All

Profile

IntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine; INT0046/2018 and INT0055/2021 are for adult use; INT0007/2006, an oral film product for treatment of erectile dysfunction; INT0043/2015, an oral film containing montelukast for treatment of Alzheimer; INT0027/2011 to treat opioid addition; INT0010/2006 for treatment of neuropathic pain and nausea in cancer patients undergoing chemotherapy; INT0036/2013, an oral film product for schizophrenia or bipolar 1 disorder; and INT0048/2020 for animal health. It is also developing INT0039/2013, INT0053/2020, and INT0054/2020. The company has licensing, development, and supply agreement with Tilray, Inc.; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was incorporated in 1999 and is headquartered in Montreal, Canada.

Intelgenx Technologs

6420 Abrams, Montreal, QC, Canada, H4S 1Y2

Key Executives

Name Title Year Born
Dr. Horst G. Zerbe Ph.D. Chairman, CEO & Chairman of Scientific Advisory Board 1947
Mr. André Godin C.A., CPA, CA, CPA Pres & CFO 1964
Mr. Tommy Kenny J.D., L.L.B., M.Sc. VP of Intellectual Property & Legal Affairs and Gen. Counsel 1987
Ms. Nadine Paiement Vice-Chair of Scientific Advisory Board and VP of R&D - IntelGenx Corp 1977
Stephen Kilmer Investor Relations Officer NA
Ms. Ingrid Zerbe Corp. Sec. 1954

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).